{
    "nct_id": "NCT03636256",
    "official_title": "Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma",
    "inclusion_criteria": "* Signed informed consent;\n* Age ≥18 years;\n* Patients with either:\n\n  * High-risk Non-Muscle Invasive Bladder Cancer (NMIBC);\n  * Muscle Invasive Bladder Cancer (MIBC);\n* Urothelial carcinoma confirmed by biopsy, urine cytology, computed tomography scan (CT) or other institution-approved diagnostic methodology;\n* All visible tumors removed during bladder resection (TURBT);\n* Performance Status (ECOG) 0-2 at study entry;\n* Life expectancy of at least 6 months;\n* Adequate marrow, liver, and renal function;\n\n  * ANC ≥ 1.5 x 10^9/L;\n  * Hemoglobin ≥ 9.5 grams/dL;\n  * Platelets ≥ 75 x 10^9/L;\n  * Total bilirubin ≤ 1.5x institutional ULN;\n  * AST/ ALT ≤ 2.5x institutional ULN;\n  * Creatinine ≤ 1.5x institutional ULN;\n* Adequate method of birth control.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic disease;\n* Previous (within 12 months) or concurrent history of non-bladder malignancy, except for non-melanoma skin cancer;\n* Intravesical therapy within 6 weeks prior to consent (chemotherapy or immunotherapy including BCG administered directly into the bladder);\n* Resection surface area greater than 8 cm2;\n* Upper tract and urethral disease within 18 months;\n* Known hypersensitivity to any of the study drug components or reconstitution components;\n* Pregnant or breastfeeding;\n* Participation in the treatment phase of another clinical trial within 3 months prior to consent;\n* Investigator's opinion of subject's probable noncompliance or inability to understand the trial and/or give adequate informed consent;\n* Ongoing drug or alcohol abuse.",
    "miscellaneous_criteria": ""
}